Suppr超能文献

成人腺苷脱氨酶缺乏症。

Adenosine deaminase deficiency in adults.

作者信息

Ozsahin H, Arredondo-Vega F X, Santisteban I, Fuhrer H, Tuchschmid P, Jochum W, Aguzzi A, Lederman H M, Fleischman A, Winkelstein J A, Seger R A, Hershfield M S

机构信息

Division of Immunology/Hematology, University Children's Hospital, Zurich, Switzerland.

出版信息

Blood. 1997 Apr 15;89(8):2849-55.

PMID:9108404
Abstract

Adenosine deaminase (ADA) deficiency typically causes severe combined immunodeficiency (SCID) in infants. We report metabolic, immunologic, and genetic findings in two ADA-deficient adults with distinct phenotypes. Patient no. 1 (39 years of age) had combined immunodeficiency. She had frequent infections, lymphopenia, and recurrent hepatitis as a child but did relatively well in her second and third decades. Then she developed chronic sinopulmonary infections, including tuberculosis, and hepatobiliary disease; she died of viral leukoencephalopathy at 40 years of age. Patient no. 2, a healthy 28-year-old man with normal immune function, was identified after his niece died of SCID. Both patients lacked erythrocyte ADA activity but had only modestly elevated deoxyadenosine nucleotides. Both were heteroallelic for missense mutations: patient no. 1, G216R and P126Q (novel); patient no. 2, R101Q and A215T. Three of these mutations eliminated ADA activity, but A215T reduced activity by only 85%. Owing to a single nucleotide change in the middle of exon 7, A215T also appeared to induce exon 7 skipping. ADA deficiency is treatable and should be considered in older patients with unexplained lymphopenia and immune deficiency, who may also manifest autoimmunity or unexplained hepatobiliary disease. Metabolic status and genotype may help in assessing prognosis of more mildly affected patients.

摘要

腺苷脱氨酶(ADA)缺乏通常会导致婴儿严重联合免疫缺陷(SCID)。我们报告了两名具有不同表型的ADA缺乏成年患者的代谢、免疫和基因研究结果。患者1(39岁)有联合免疫缺陷。她小时候频繁感染、淋巴细胞减少且反复出现肝炎,但在二三十岁时情况相对较好。随后她出现慢性鼻窦肺部感染,包括肺结核,以及肝胆疾病;40岁时死于病毒性白质脑病。患者2是一名28岁健康男性,免疫功能正常,在他侄女死于SCID后被确诊。两名患者红细胞ADA活性均缺乏,但脱氧腺苷核苷酸仅轻度升高。两人均为错义突变的杂合子:患者1为G216R和P126Q(新发现);患者2为R101Q和A215T。其中三个突变消除了ADA活性,但A215T仅使活性降低85%。由于外显子7中间的单个核苷酸变化,A215T似乎还诱导了外显子7跳跃。ADA缺乏是可治疗的,对于年龄较大、有不明原因淋巴细胞减少和免疫缺陷,且可能表现出自身免疫或不明原因肝胆疾病的患者应考虑此病。代谢状态和基因型可能有助于评估病情较轻患者的预后。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验